坤复康胶囊对盆腔炎性疾病后遗症疗效及红细胞免疫、血浆TXB2、6-Keto-PGFlα的影响

Influence of Kunfukang Capsules on Sequela Effect and Erythrocyte Immune,Plasma Thromboxane B2,6-Keto-PGFlα in Patients with Chronic Pelvic Inflammatory Disease

【目的】探讨坤复康胶囊治疗湿热瘀结型盆腔炎性疾病后遗症(CPID)的疗效及对患者红细胞免疫、血浆血栓素B2(TXB2)和6-酮前列腺素Flα(6-Keto-PGFlα)的影响。【方法】将70例湿热瘀结型CPID患者随机分为观察组和对照组,每组各35例。观察组给予口服坤复康胶囊治疗,对照组给予口服花红片治疗,20 d为1个疗程,治疗2个疗程,经期停药。观察2组患者治疗前后中医证候评分、CPID局部体征评分及红细胞免疫[C3b受体花环率(E-C3bRR)和红细胞免疫复合物花环率(E-ICR)]、血浆TXB2、6-Keto-PGFlα的变化情况。【结果】(1)观察过程中,2组各有3例患者脱落,最终2组各有32例患者完成试验。(2)治疗后,2组患者的中医证候评分及CPID局部体征评分均较治疗前明显降低(P<0.05),且观察组的降低作用均明显优于对照组(P<0.05)。(3)治疗后,2组患者的E-C3bRR水平均明显升高、E-ICR水平均明显降低(P<0.05),且观察组对E-C3bRR水平的升高作用及对E-ICR水平的降低作用均明显优于对照组(P<0.05)。(4)治疗后,观察组的TXB2水平明显降低,6-Keto-PGFlα水平明显升高(P<0.05),而对照组仅TXB2水平降低(P<0.05);组间比较,观察组对TXB2水平的降低作用明显优于对照组(P<0.05)。(5)经Spearman相关性分析,E-C3bRR与TXB2存在负相关,相关系数为-0.21,差异有统计学意义(P<0.05)。【结论】坤复康胶囊对于湿热瘀结型CPID患者具有良好的治疗效果,其机制可能与有效提高红细胞CR1含量及活性,改善CPID患者血管因子水平有关。

Objective To study the clinical efficacy of Kunfukang Capsules for the treatment of sequela of chronic pelvic inflammatory disease(CPID)with damp-heat and blood stasis accumulation syndrome,and to observe the effects of the capsules on the erythrocyte immune,plasma thromboxane B2(TXB2),and 6-ketone prostaglandin F1α(6-Keto-PGF1α). Methods Seventy cases of CPID with damp-heat and blood stasis accumulation syndrome were randomly divided into observation group and control group,35 cases in each group. The observation group was given oral use of Kunfukang Capsules,and the control group was given oral use of Huahong Capsules. Twenty days constituted one course of treatment,and the two groups had the medication of 2 courses,and the medication was suspended during the menstrual cycle. Before and after treatment,the scores of traditional Chinese medicine(TCM)syndrome, the scores of focal signs of CPID, and erythrocyte immune indicators of erythrocyte C3b receptor rosette rate(E-C3bRR)and erythrocyte immunocomplex rosette rate(E-ICR), and plasma levels of TXB2 and 6-Keto-PGF1α in the two groups were observed. Results(1)During the trial,3 cases from the observation group and 3 cases from the control group dropped out,and a total of 32 cases of each group finished the trial.(2)After treatment,the scores of TCM syndrome and the scores of focal signs of CPID in the two groups were obviously decreased in comparison with those before treatment(P<0.05),and the decrease in the observation group was superior to that in the control group(P < 0.05).(3)After treatment,the E-C3bRR was obviously increased and E-ICR was obviously decreased in the two groups as compared with those before treatment(P<0.05),and the observation group had stronger effect on increasing E-C3bRR and on decreasing E-ICR than the control group(P < 0.05).(4)After treatment,the TXB2 level was obviously decreased in the two groups and 6-Keto-PGF1αlevel was obviously increased in the observation group as compared with those before treatment(P<0.05),and the intergroup comparison showed that the observation group had stronger effect on decreasing TXB2 level than the control group(P < 0.05).(5)The Spearman analysis showed that E-C3bRR rate was negatively correlated with TXB2 level,and the correlation coefficient was-0.21,the difference being statistically significant(P < 0.05).Conclusion Kunfukang Capsules have definite effect for the treatment of sequela of CPID with damp-heat and blood stasis accumulation syndrome, and their mechanism may be related with the increase of erythrocyte complement receptor 1(CR1)content and activity and with the improvement of CPID vascular factor levels.